Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Arcturus Therapeutics (Nasdaq: ARCT) reported a narrower third-quarter 2026 net loss of $7.4 million while outlining clinical development milestones. Revenue rose to $18.3 million from $17.2 million a year earlier, reflecting a $12.0 million CSL Seqirus termination payment and remaining deferred revenue recognition. Nine-month revenue fell to $23.3 million from $74.8 million, while net loss widened to $58.2 million from $36.7 million.
Cash totaled $184.8 million at September 30, down $46.1 million from year-end 2025; the company expects funding to last through year-end 2028. Arcturus expects ARCT-032 enrollment completion by year-end 2026 and data presentation in Q2 2027. It plans ARCT-2601 Phase 2 dosing in Q1 2027, with top-line data expected in H2 2027. ARCT-810 interim results showed ammonia and glutamine biomarker activity and generally favorable tolerability. The myNEO acquisition is complete.
Arcturus Therapeutics (ARCT) will release its third-quarter financial results after market close on November 5, 2026, and provide a corporate update.
The results cover the quarter ended September 30, 2026. A conference call and webcast will follow at 4:30 p.m. Eastern Time on November 5.
Arcturus Therapeutics (ARCT) reported interim Phase 2 ARCT-810 results in OTC deficiency and introduced its LUNAR 2.0 mRNA delivery platform.
ARCT-810 was generally safe and well tolerated in the ongoing study. First morning fasting ammonia fell or remained within the normal range, including during increased protein intake. Glutamine fell; participants at the 0.5 mg/kg dose level had mean values within the normal range during treatment. In separate nonhuman primate studies, LUNAR 2.0 showed a 40-fold improvement over LUNAR 1.0 in human erythropoietin expression and 38-fold greater potency than ATX-95 in human OTC expression.
Arcturus plans to begin dosing LUNAR 2.0-based ARCT-2601 near year-end in participants aged 12 and older under an amended Phase 2 protocol. It also signed a definitive agreement to acquire myNEO, subject to customary closing conditions, with closing expected in October.
Arcturus Therapeutics (ARCT) will host a virtual presentation on September 23, 2026, at 4:30 p.m. ET to review the ARCT‑810 Phase 2 program for ornithine transcarbamylase (OTC) deficiency and outline its mRNA liver therapeutics platform.
The event will feature Marshall Summar, M.D., an internationally recognized expert in urea cycle disorders, who will discuss OTC deficiency and its clinical context. The company plans to issue a separate press release summarizing the presentation content before the call.
ARCT‑810 is an investigational intravenously administered mRNA therapeutic designed to express functional OTC enzyme in the liver. It has received Orphan Medicinal Product Designation and an approved pediatric investigation plan from the EMA, and Orphan Drug, Fast Track and Rare Pediatric Disease Designations from the FDA for treatment of OTC deficiency.
Arcturus Therapeutics (Nasdaq: ARCT), a messenger RNA medicines company focused on liver and respiratory rare disease therapeutics, will participate in several September 2026 investor conferences, including Wells Fargo, Citi, Cantor Fitzgerald, H.C. Wainwright, and ROTH events, featuring fireside chats, a presentation, and investor meetings.
According to Arcturus, events run from September 8–29, 2026/b) in Boston and New York, with specific Eastern Time slots for each appearance. Webcast links are available in the section of the company’s website.
Arcturus Therapeutics (Nasdaq: ARCT) reported second quarter 2026 results and pipeline updates, including continued enrollment in the Phase 2 ARCT-032 cystic fibrosis study and completed enrollment and dosing in the Phase 2 ARCT-810 OTC deficiency study. A decision on advancing ARCT-032 to Phase 3 is expected in Q4 2026, supported by a strategic collaboration in which Thermo Fisher will provide Phase 3 manufacturing and clinical research services and, subject to approval, hold exclusive commercial manufacturing rights.
Arcturus and CSL Seqirus terminated their sa-mRNA collaboration, with Arcturus regaining global rights to KOSTAIVE® and its infectious disease vaccine portfolio. According to the company, CSL Seqirus will pay $12 million in cash and release Arcturus from approximately $16 million of R&D-related liabilities. Q2 2026 revenue declined to $3.0 million from $28.3 million a year earlier, R&D expenses fell to $17.5 million from $29.6 million, and net loss widened to $23.8 million from $9.2 million. Cash and cash equivalents were $191.5 million, with management indicating a cash runway of over two and a half years through year-end 2028.
Arcturus Therapeutics (Nasdaq: ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, plans to release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, August 6, 2026.
The company will host a Second Quarter 2026 earnings conference call and webcast at 4:30 p.m. Eastern Time the same day. Investors can join via domestic dial-in 1-800-347-6865, international dial-in 1-203-518-9757, using Conference ID: ARCTURUS, or access the event through an online webcast link.
Arcturus Therapeutics (Nasdaq: ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, Massachusetts.
The company is scheduled for a fireside chat on Tuesday, August 11, 2026 at 12:00 p.m. ET, with a webcast available through the Investor Relations/Events section of its website. Arcturus highlights its LUNAR delivery, STARR sa-mRNA technology, mRNA manufacturing capabilities, the approved sa-mRNA COVID vaccine KOSTAIVE, collaborations with CSL Seqirus and BARDA, its ARCALIS joint venture in Japan, and a rare disease and vaccine pipeline supported by an extensive global patent portfolio.
Arcturus Therapeutics (Nasdaq: ARCT) announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.
The agreement covers Phase 3 clinical supply, integrated manufacturing, clinical research, and exclusive commercial manufacturing rights, subject to positive Phase 2 results and regulatory approval.
Arcturus Therapeutics (Nasdaq:ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, will present at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026 at 9:20 a.m. ET, with a webcast available via the company’s investor relations website.